Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyHodgkin LymphomaIndolent LymphomasTransplantationDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C83.7C84.4C88.0-C91.0-C91.1-MeSHLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, T-Cell, PeripheralPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceIXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)MOSU(1/2/60), B-NHL, C1 (PID2105) -|- C2 (PID2106) -|- C3+ (PID2107)ChemotherapyChemo-substanceCarboplatinCarmustineCyclophosphamideCytarabineDexamethasoneEtoposideFludarabineMelphalanMosunetuzumabRituximabTazemetostatChemo-substanceCarboplatinCarmustineCyclophosphamideCytarabineDexamethasoneEtoposideFludarabineMelphalanMosunetuzumabRituximabTazemetostatChemo-substanceCarboplatinCarmustineCyclophosphamideCytarabineDexamethasoneEtoposideFludarabineMelphalanMosunetuzumabRituximabTazemetostatChemo-substanceCarboplatinCarmustineCyclophosphamideCytarabineDexamethasoneEtoposideFludarabineMelphalanMosunetuzumabRituximabTazemetostatNo. Substances12346 RadiotherapySupportive therapySupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneNo. Substances3567Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationRelapse therapyseveral possibleTherapy phaseInductionSalvageTherapy intentioncurativedisease controlpalliativeRisksAnemia Hb below 8g/dlCytokine Release SyndromeDiarrheaDyspneaEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHyperglycemiaHypertensionHypokalemiaHypophosphatemiaIncrease AminotransferasesInfectionsLymphopeniaNauseaNeuropathyNeutropeniaPneumoniaSepsisThrombocytopenia below 50 000/µlVomiting only studiesPublicationAuthorBudde LEDavies AKirschey SLiu E Morschhauser FTessoulin BDiseaseB-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieB-Non-Hodgkin-Lymphom/Hodgkin LymphomNon-Hodgkin-Lymphom / Hodgkin LymphomRefraktäres oder rezidiviertes follikuläres Lymphom °I-IIIb, Drittlinie, ECOG 0-2rezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2rezidiviertes oder refraktäres B-NHL, mindestens zwei vorherige systemische BehandlungenOriginCancer Research UK Centre, University of Southampton, UK, SABRINA StudieCity of Hope National Medical Center, Duarte, CADepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzGroupe de Recherche sur les formes Injectables et les Technologies Associées, Université de Lille, FranceNantes Medical University, Nantes, FranceUniversity of Texas M.D. Anderson Cancer Center, HoustonProtocols in Revision 9 protocols foundProtocols under revision.DHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346 V1.0)Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471 V2.0)Mosunetuzumab (1/2/60), B-Non-Hodgkin Lymphoma, cycle 1 (PID2105 V1.0)Mosunetuzumab 30, B-Non-Hodgkin Lymphoma, cycle 3+ (PID2107 V1.0)Mosunetuzumab 60, B-Non-Hodgkin lymphoma, cycle 2 (PID2106 V1.0)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)R-DHAC - Rituximab 375 / Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, B-Non-Hodgkin's Lymphoma/Hodgkin's Lymphoma (PID2345 V1.0)Rituximab 1400, single dose subcutaneous (PID310 V2.0)Tazemetostat 800, follicular Lymphoma (PID2829 V1.0)
